Literature DB >> 3510572

Antidepressant effects of carbamazepine.

R M Post, T W Uhde, P P Roy-Byrne, R T Joffe.   

Abstract

Thirty-five depressed patients diagnosed by DSM-III criteria participated in a double-blind study of the acute antidepressant effects of the anticonvulsant carbamazepine, at average doses of 971 mg/day, achieving mean +/- SD blood levels of 9.3 +/- 1.9 micrograms/ml (range, 3-12.5 micrograms/ml). Twenty patients (57%) showed at least mild improvement, and 12 showed more substantial improvement. Possible clinical predictors of antidepressant response to carbamazepine are discussed. These preliminary data suggest that carbamazepine has some acute antidepressant efficacy in addition to the growing evidence that it has acute antimanic and longer-term prophylactic efficacy in both phases of manic-depressive illness.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510572     DOI: 10.1176/ajp.143.1.29

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  20 in total

Review 1.  Bipolar depression: management options.

Authors:  Gin S Malhi; Philip B Mitchell; Shahzad Salim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Carbamazepine in bipolar disorder with pain: reviewing treatment guidelines.

Authors:  Tahir Rahman; Austin Campbell; Christopher R O'Connell; Kishan Nallapula
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-09

3.  [Not Available].

Authors:  U Thoden
Journal:  Schmerz       Date:  1992-03       Impact factor: 1.107

Review 4.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

5.  Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.

Authors:  Anita Rakic Ignjatovic; Branislava Miljkovic; Dejan Todorovic; Ivana Timotijevic; Milena Pokrajac
Journal:  Br J Clin Pharmacol       Date:  2008-12-05       Impact factor: 4.335

Review 6.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

Review 7.  Managing resistant depression. When patients do not respond to therapy.

Authors:  L Warneke
Journal:  Can Fam Physician       Date:  1993-04       Impact factor: 3.275

8.  Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

Authors:  W Daniel; L Janczar; L Danek; W Legrum; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

9.  Evolving refractory major depressive disorder diagnostic and treatment paradigms: toward closed-loop therapeutics.

Authors:  Matthew P Ward; Pedro P Irazoqui
Journal:  Front Neuroeng       Date:  2010-05-31

10.  Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder.

Authors:  S L Dubovsky; M Thomas; A Hijazi; J Murphy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.